Change in leadership at UMC – WHO Collaborating Centre Uppsala, Sweden

WHO programme / 30 March 2022

Prof. Hervé Le Louët has resigned from his position as CEO of UMC due to family reasons. The recruitment process for next CEO starts immediately. During this interim period, Deputy CEO and former CFO, Birgitta Lindner, will serve as acting CEO, with full support from the Board.

During Le Louët’s tenure as CEO, UMC delivered impressive results. He helped drive forward necessary structural and strategic changes that will continue to be implemented. The Board thanks him for his work and wishes him all the best in the next phase of his career.

UMC’s dedicated and skilled staff will continue business as usual, pursuing their duties in line with the strategy and assignments set by the Board.

You may also like


Promoting pharmacovigilance in Azerbaijan

In January 2018, the national centre of Azerbaijan became the 130th full member of the WHO Programme for International Drug Monitoring - and there is much progress to report.

WHO programme / 23 June 2022

Luxembourg's PV culture: a lesson in the benefits of cross-pollination

Luxembourg joined the WHO Programme for International Drug Monitoring in 2020, and being part of the network has already supported the growth of the pharmacovigilance department.

WHO programme / 04 May 2022

WHO programme member update – March 2021

Recent additions mean the WHO Programme for International Drug Monitoring now stands at 143 full members and 28 associate members.

WHO programme / 30 March 2021

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more